require 'faker'


puts "ðŸŒ± planting seeds..."

# response = RestClient.get('https://clinicaltrials.gov/api/query/full_studies?expr=cell+therapy&min_rnk=1&max_rnk=&fmt=json')
# trials_array = JSON.parse(response)

# nest1 = trials_array["FullStudiesResponse"]
# nest2 = nest1["FullStudies"]
# nest3 = nest2.each do |studies|
#     studies["Study"]
# end

# binding.pry

#1 --------------------------------------------
Trial.create(NCTId: "NCT04115345", organization_name: "Prokidney", brief_title: "A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).", official_title: "A Phase 1 Open-Label Safety, Tolerability, and Early Efficacy Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) (REGEN-004)", overall_status: "Completed", start_date: "August 13, 2019", primary_completion_date: "January 31, 2023", primary_completion_date_type: "Actual", lead_sponsor: "Prokidney", is_fda_regulated_drug: "Yes", is_fda_regulated_device: "No", brief_summary: "A phase 1, open-label safety, tolerability and early efficacy study of a Renal Autologous Cell Therapy (REACT) in patients with Chronic Kidney Disease from Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) (REGEN-004)", detailed_description: "It is anticipated that all subjects will receive two planned Renal Autologous Cell Therapy (REACT) injections to allow dose-finding and evaluate the duration of effects. The scientific rationale, based on non-clinical studies, is that the biologically active component of REACT (homologous, autologous, SRC) delays progression of experimental models of Chronic Kidney Disease (CKD) by augmenting renal structure and function. As a result, the more cells that can be infused, the greater the potential improvement in renal function.", study_type: "Interventional", phase: "Phase 1", intervention_type: "Biological", intervention_description: "Autologous selected renal cells (SRC)", eligibility_criteria: "Inclusion Criteria: The patient is male or female, 18 to 65 years of age on the date of informed consent.The patient has a documented history of a corrected abnormality of the kidney and/or urinary tract (CAKUT) leading to renal dysfunction. The patient has an established diagnosis of Stage III/IV CKD not requiring renal dialysis. The subject has blood pressure less than 150/90 at the Screening Visit, prior to renal biopsy, and prior to REACT injection(s). Exclusion Criteria: The patient has a history of renal transplantation. The patient has a diagnosis of hydronephrosis, SFU Grade 4 or 5. The patient has an uncorrected VUR Grade 5. The patient has a diffuse cortical thickness throughout the kidney measuring < 5 mm on MRI that prevents safe cortical biopsy.", gender: "All", minimum_age: "18 Years", contact_name: "Ashley Johns", contact_phone: "N/A", contact_email: "N/A")

ArmGroup.create(trial_id: 1, label: "Renal Autologous Cell Therapy (REACT)", group_type: "Experimental", description: "The volume of REACT to be administered will be determined by pre-procedure MRI volumetric 3D evaluation or ellipsoid formula. The participant will receive a second injection 6 months after the first injection into the same kidney.", intervention_name: "Biological: Renal Autologous Cell Therapy (REACT)")

Outcome.create(trial_id: 1, outcome_type: "primary", outcome_measure: "Assess change in eGFR and observe incidence of renal-specific procedure and/or product related adverse events (AEs) through 18 months following two Renal Autologous Cell Therapy (REACT) injections [Safety].", outcome_description: "The primary objective is to assess the safety and optimal delivery of Renal Autologous Cell Therapy (REACT) injected at one site in a recipient kidney as measured by procedure- and/or product related adverse events (AEs) through 18 months post-treatment.", outcome_timeframe: "18 months following last REACT injection")

Condition.create(trial_id: 1, condition: "Kidney Diseases")
Condition.create(trial_id: 1, condition: "Renal Insufficiency, Chronic")
Condition.create(trial_id: 1, condition: "Congenital Abnormalities")
Condition.create(trial_id: 1, condition: "Urologic Diseases")
Condition.create(trial_id: 1, condition: "Renal Insufficiency")

Location.create(trial_id: 1, facility: "Emory University Hospital", city: "Atlanta", state: "Georgia", zip: "30322", country: "United States")
Location.create(trial_id: 1, facility: "Hackensack Meridian Jersey Shore University Medical Center", city: "Neptune", state: "New Jersey", zip: "07753", country: "United States")
Location.create(trial_id: 1, facility: "Boise Kidney & Hypertension Institute", city: "Meridian", state: "Idaho", zip: "83642", country: "United States")
Location.create(trial_id: 1, facility: "Mt. Sinai Hospital", city: "New York", state: "New York", zip: "45246", country: "United States")

#2 --------------------------------------------
Trial.create(NCTId: "NCT05414162", organization_name: "University Hospital, Bonn", brief_title: "Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy", official_title: "Multiparametric Cardiac MRI in Oncological Patients Under Chimeric Antigen Receptor T-Cell Therapy", overall_status: "Recruiting", start_date: "May 16, 2022", primary_completion_date: "May 2024", primary_completion_date_type: "Anticipated", lead_sponsor: "University Hospital, Bonn", is_fda_regulated_drug: "No", is_fda_regulated_device: "N/A", brief_summary: "Recently chimeric antigen receptor (CAR) T-cell therapy, a new class of chemo therapy, has gained regulatory approval for the treatment of diseases such as B-cell lymphoma. Known side effects include cytokine release syndrome, which has been described to lead to myocarditis, but larger studies exploring this relationship are currently lacking. In this prospective study, the investigators aim to explore the potential effects of CAR T-cell therapy using cardiac MRI on the heart.", detailed_description: "Genetically modified chimeric antigen receptor (CAR) T cells specifically targeting CD19 or B cell maturation antigen (BCMA) have shown remarkable advances in the treatment of highly refractory and relapsing hematological malignancies including diffuse large B-cell lymphoma or multiple myeloma. However, this potent therapy is hampered by serious, potentially life threatening complications, which might also involve the cardiovascular system. The potential cardiotoxic profile remains poorly defined and insufficiently understood. This proposal describes a prospective, longitudinal, intraindividual cardiac magnetic resonance imaging (MRI) study in oncological patients, which are scheduled for CAR T cell therapy for cancer treatment. This explorative study is designed to evaluate and monitor acute and late effects of CAR T cell therapy on the heart muscle. Systematic cardiac MRI monitoring correlated with the clinical course and thorough immunological assessment is the next step in helping to understand the extent, pattern, and pathophysiology of CAR T cell therapy related cardiovascular adverse events.A chimeric antigen receptor (CAR) is a recombinant fusion protein that activates T cells upon recognition of a specific antigen on the cell surface of target cells. Therapeutic success was especially noticed with CD19-specific CAR T cells in the treatment of highly refractory and relapsing hematological malignancies. CD19 is an effective target due to its expression throughout the development line of B cells and has a frequent and high-level expression on the surface of nearly all B-cell malignancies. In addition, it is not found on other normal tissue cells, including the heart, and is not shed as a soluble form. The process of manufacturing CAR T cells typically requires 3 to 4 weeks. Autologous T cells are first collected from the patient and then genetically modified ex vivo with lentiviral or retroviral vectors to reprogram the T cells to recognize tumor cells expressing a tumor associated antigen (e.g., CD19 or BCMA). The CAR T cells a multiplied in large quantities before being administered to the patient within a single infusion. Before the infusion of CAR T cells, patients undergo lymphodepleting chemotherapy, most commonly with a combination of fludarabine and cyclophosphamide. This suppresses the patient's endogenous T cell compartment and allows an in vivo expansion of the transferred CAR T cells. Although the CAR T cell therapy has clearly advanced the treatment of highly refractory or relapsing hematological malignancies, there are potentially severe drawbacks of this therapy. One especially worrisome shortcoming is the potential therapy association with the unique toxicities of a cytokine release syndrome (CRS) and neurologic toxicities.Cardiovascular complications associated with CAR T cell therapy are less well defined but can be subclassified into autoimmune toxicities resulting from antigen-specific T cell infiltration of the heart and cytokine-mediated toxicities. Cytokine-associated cardiotoxicities have been reported especially in the setting of CRS and might be the cause for most of the observed cardiovascular side effects. In a retrospective study from Alvi et al. cardiovascular events were systematically investigated in adults treated with CAR T cell therapy. The study included 137 patients and found that up to 12% of patients had clinical apparent cardiovascular events after CAR T cell therapy initiation (median time to event 21 days). Cardiovascular events included cardiovascular death, new onset heart failure, decompensated heart failure, and new onset of arrhythmia. A decrease in left ventricular function was observed in 28% of patients while 54% of patients had an elevated troponin. Interestingly, all cardiovascular events occurred in patients with grade â‰¥ 2 CRS and 95% of events occurred after troponin elevation. Another retrospective study from Lefebvre et al. investigated the occurrence of major adverse cardiovascular events (MACE) in 145 adult patients treated with CAR T cell therapy. MACE included cardiovascular death, symptomatic heart failure, acute coronary syndrome, ischemic stroke, and new onset arrhythmias. In total, 31 out of 145 (21%) patients had MACE at a median time of 11 days after CAR T cell infusion. MACE was independently associated with CRS grade 3 or 4 and baseline creatinine. Overall survival after one year was 71%. Another retrospective study analyzing 116 patients with serial echocardiograms after CAR T cell therapy found that 10% of patients developed a new cardiomyopathy with a decrease of left ventricular ejection fraction (average decrease from 58% to 37%), mostly observed in patients with grade â‰¥ 2 CRS. Another study with a patient pool of 126, found that 10% of patients developed severe cardiac disorders after CAR T cell therapy including new onset heart failure, acute coronary syndrome, and myocardial infarction.Cardiac MRI for assessment of acute and chronic cardiac effects in CAR T cell therapy As the impact and the pathophysiology of cardiotoxicity of CAR T cell therapies to the heart is poorly understood, it is still unclear, whether cardiotoxicity is simply an early phenomenon associated with the cytokine storm within the scope of the CRS or whether there are more direct cardiotoxic effects from the CAR T cells themselves. It has also been proposed that the observed systolic dysfunction in this setting is a sequalae of a stress induced Takotsubo syndrome. In this context, the physiological stress from the CRS could trigger the occurrence of Takotsubo syndrome. To explore the extent of cardiac injury and inflammation and the pattern of myocardial involvement related to CAR T cell therapy, cardiac MRI must be considered as the imaging modality of choice, particularly due to its inherent capabilities of advanced tissue characterization. Cardiac MRI can characterize myocardial tissue alterations, analyze involvement patterns, and give important insights into the remodeling processes. To date, no cardiac MRI studies in patients with CAR T cell therapy exist. However, in this context, multiparametric cardiac MRI can be used to detect and quantify acute diffuse myocardial tissue alterations, such as myocardial edema and fibrosis. Furthermore, alterations in myocardial function can be detected with high sensitivity by using myocardial strain analysis. Late gadolinium enhancement imaging has a very high specificity for the detection of necrotic inflammatory lesions, especially in the context of inflammatory cardiomyopathies, and could directly show inflammatory lesions associated with CAR T cell therapy. Also, cardiac MRI could reliably identify different patterns of wall motion abnormalities which are associated with Takotsubo syndrome (i.e., apical, midventricular, basal or focal types). A recent study from our group in patients under immune checkpoint inhibitors (ICI) for cancer treatment suggests that cardiac MRI is able to show subtle therapy related treatment effects and can support evidence of a specific imaging pattern of ICI-related myocarditis. Also, cardiac MRI is the imaging modality of choice to show longterm, cardiotoxic effects of chemotherapy. It is considered the reference standard for measurement of ventricular volumes and function making it ideally suited to assess adverse cardiac remodeling after termination of cancer treatment.", study_type: "Observational", phase: "N/A", intervention_type: "Diagnostic Test", intervention_description: "Hematooncology patients under CAR T-cell therapy will receive 3 MRI examinations: at baseline, within 2 weeks of start of CAR T-cell therapy, and at 6 months follow-up.", gender: "All", minimum_age: "18 Years", contact_name: "Julian Luetkens, MD", contact_phone: "+49 228 287 11831", contact_email: "julian.luetkens@ukbonn.de")

ArmGroup.create(trial_id: 2, label: "CAR T-cell Therapy Group", group_type: "N/A", description: "Hematooncological patients undergoing CAR T-cell therapy with Tisagenlecleucel, Axicabtagen-ciloleucel, Idecabtagen-vicleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel or Ciltacabtagene Autoleucel (dosages, frequency and duration to be determined by the treating oncologist).", intervention_name: "Diagnostic Test: Cardiac MRI")

Outcome.create(trial_id: 2, outcome_type: "primary", outcome_measure: "Extent and pattern of acute cardiac effects of CAR T-cell therapy", outcome_description: "To investigate to what extent and with which patterns CAR T cell therapy leads to acute cardiac effects in terms of inflammation, fibrosis, and myocardial dysfunction that can be detected with cardiac MRI.", outcome_timeframe: "2 weeks")
Outcome.create(trial_id: 2, outcome_type: "secondary", outcome_measure: "Long-term cardiac remodeling effects of CAR T-cell therapy", outcome_description: "To explore whether CAR T cell therapy leads to long-term cardiac remodeling effects in terms of inflammation, fibrosis, and myocardial dysfunction that can be detected with cardiac MRI.", outcome_timeframe: "6 months")
Outcome.create(trial_id: 2, outcome_type: "secondary", outcome_measure: "Correlate MRI findings with clinical course", outcome_description: "To assess whether changes in cardiac MRI parameters obtained from objectives 1 and 2 correlate with the clinical course (e.g., CRS development), cytokines and immunological markers and might predict major adverse cardiac events (MACE).", outcome_timeframe: "6 months")

Condition.create(trial_id: 2, condition: "Multiple Myeloma")
Condition.create(trial_id: 2, condition: "Myocarditis")
Condition.create(trial_id: 2, condition: "Cytokine Release Syndrome")

Location.create(trial_id: 2, facility: "University Hospital Bonn", city: "Bonn", state: "NRW", zip: "53127", country: "Germany")

#3 --------------------------------------------
Trial.create(NCTId: "NCT01824121", organization_name: "Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico", brief_title: "Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism", official_title: "Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial", overall_status: "Recruiting", start_date: "December 2012", primary_completion_date: "December 2014", primary_completion_date_type: "Anticipated", lead_sponsor: "Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico", is_fda_regulated_drug: "No", is_fda_regulated_device: "No", brief_summary: "There is evidence suggesting that stem cells harvested from the bone marrow and transplanted into the brain may be effective in slowing down the progression of parkinsonism. Mesenchymal stem cells are able to produce growth factors that provide support to diseased nervous cells.In this study mesenchymal stem cells will be harvested from the bone marrow, cultivated in a test tube so that they multiply and then infused into the arteries that supply blood to the brain in 20 patients suffering from a rare form of parkinsonism, Progressive Supranuclear Palsy. Each patient will undergo two infusions, one with the stem cells and one without, at an interval of 6 months. The sequence of the two infusions will be assigned randomly; patients and assessors will not know the sequence (double-blind). Patients will be followed-up for up to 1 year after the last infusion, with regular assessments to assess safety, efficacy on motor and cognitive functions, and effects on the brain by neuroimaging techniques.The study has a preliminary phase with 5 patients all given stem cell therapy alone, designed to assess safety", detailed_description: "N/A", study_type: "", phase: "Phase 1", intervention_type: "Biological", intervention_description: "Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.", eligibility_criteria: "Inclusion Criteria: diagnosis of 'probable Progressive Supranuclear Palsy - Richardson's disease subtype' according to current diagnostic criteria (Litvan et al. 1996 and 2003) age at onset at least 40 years; disease duration 12 months to 8 years; supranuclear ophthalmoplegia; postural instability or falls within 3 years from disease onset positive MRI for PSP criteria (Quattrone et al, 2008) Stable pharmacological treatment for at least 90 days. Lack of response to chronic levodopa (at least 12-month treatment). Able to stand in upright posture without assistance for at least 30 seconds. Written informed consent (including video taping). Exclusion Criteria: Idiopathic Parkinson's disease;Cerebellar ataxia. Symptomatic autonomic dysfunction. Evidence of any other neurological disease that could explain signs; History of repeated strokes with stepwise progression of parkinsonian features; History of major stroke; Any history of severe or repeated head injury; A history of encephalitis; A history of neuroleptic use for a prolonged period of time or within the past 6 months; Street-drug related parkinsonism; Significant other neurological disease on CT-scan/MRI; Oculogyric crises; Major signs of corticobasal degeneration; Signs of Lewy body disease;Other life-threatening disease likely to interfere with the main outcome measure; Any clinically significant laboratory abnormality, with the exception of cholesterol, triglycerides and glucose; Renal failure (serum creatinine more than 300 mM/l); Transaminase elevation more than twice the upper limit of normal; Any concomitant disorder associated with bone marrow function impairment; Any concomitant disorder that requires chronic treatment with immunosuppressors, anti-inflammatory agents, and/or growth factors dementia (MMSE < 24 according to Folstein 1975 or defined according to DSM-IV TR criteria) any other disorder that could interfere with the evaluation of treatment or that could make intra-arterial infusion inadvisable any other features that, according to the investigator, could reduce adherence to protocol procedures or prevent rapid access in case of emergency; women of child-bearing age participation in another clinical trial with experimental treatment in the last 30 days brain MRI evidence of severe vascular abnormalities, space-occupying lesions or normal pressure hydrocephalus", gender: "All", minimum_age: "18 Years", contact_name: "Margherita Canesi, MD", contact_phone: "0039 02 5799", contact_email: "canesi@parkinson.it")

ArmGroup.create(trial_id: 3, label: "immediate stem cell therapy", group_type: "Active Comparator", description: "patients will undergo active intervention i.e. they will be given stem cell therapy immediately. After 6 months they will undergo a sham procedure.", intervention_name: "Biological: stem cell therapy")
ArmGroup.create(trial_id: 3, label: "delayed stem cell therapy", group_type: "Sham Comparator", description: "patients allocated to delayed stem cell therapy will undergo a sham procedure (incannulation of the femoral vein and infusion of saline solution). They will receive stem cell therapy after 6 months", intervention_name: "Biological: stem cell therapy")

Outcome.create(trial_id: 3, outcome_type: "primary", outcome_measure: "incidence of adverse events", outcome_description: "incidence of adverse events collected by clinical monitoring and performing routine laboratory tests", outcome_timeframe: "one year")
Outcome.create(trial_id: 3, outcome_type: "secondary", outcome_measure: "changes in brain images", outcome_description: "change vs baseline in the striatal density of dopamine transporters in SPECT brain images and in the normalized regional cerebral flow / glucose metabolism in the gray matter in PET brain images after one year", outcome_timeframe: "one year")

Condition.create(trial_id: 3, condition: "Supranuclear Palsy, Progressive")

Location.create(trial_id: 3, facility: "ICP Parkinson Institute", city: "Milano", state: "N/A", zip: "20126", country: "Italy")

#4 --------------------------------------------
Trial.create(NCTId: "NCT03179007", organization_name: "Shanghai Cell Therapy Research Institute", brief_title: "CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor", official_title: "A Clinical Study of CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for Patients With MUC1 Positive Advanced Solid Tumors", overall_status: "Unknown status", start_date: "June 7, 2017", primary_completion_date: "January 20, 2019", primary_completion_date_type: "Anticipated", lead_sponsor: "Shanghai Cell Therapy Research Institute", is_fda_regulated_drug: "No", is_fda_regulated_device: "No", brief_summary: "This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibodies (CTLA-4 and PD-1) and chimeric antigen receptor targeting MUC1 in adult patients with MUC1 positive, advanced recurrent or refractory malignant solid tumors.", detailed_description: "This study will be conducted using a phase I/II trial design to assess the safety and efficacy of the CTLA-4 and PD-1 antibodies expressing MUC1-CAR-T for patients with MUC1 positive, advanced recurrent or refractory malignant solid tumors. MUC1-CAR-T can specificly and effectively kill the MUC1 positive cancer cells, CTLA4 and PD-1 antibodies are secreted from the CAR-T cells could improve immunosuppression microenvironment, new CAR-T cells contain the advantages of CAR-T and immune checkpoint inhibitor, which is a promising therapeutic method for advanced solid tumors.\n\nThe new CAR-T therapy is applied to clinical practice as bellow. T cells are prepared from peripheral blood mononuclear cells (PBMC) by leukapheresis, and then activated and engineered to express CTLA-4 and PD-1 antibodies and chimeric antigen receptor targeting MUC1. Cells are proliferated in culture and returned to the patients by venous transfusion. A total of 40 patients may be enrolled in the study. The total duration of the study is expected to be approximately 24 months.", study_type: "Interventional", phase: "Phase 2", intervention_type: "Biological", intervention_description: "Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) Ã—10^7 cells/kg from day 18 to day 19 (Â±2 days). 2 cycles are regarded as a treatment period.", eligibility_criteria: "Inclusion Criteria: Patients with relapsed or refractory advanced solid malignancies (diagnosed by histology or cytology detection). Progressive disease and no response after at least second-line therapy. Gender unlimited, age from 18 years to 80 years. Life expectancyâ‰¥3 months. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Adequate venous access for peripheral blood mononuclear cell (PBMC) apheresis, and no other contraindications. Immunohistochemistry (IHC) score of MUC1 on tumor tissue â‰¥1+.dequate hepatic function, renal function and bone marrow function (withhin 7 days before enrollment): white blood cell (WBC)â‰¥3.0Ã—10^9/L; plateletâ‰¥100Ã—10^9/L; hemoglobinâ‰¥90 g/L; lymphocyte â‰¥0.7Ã—10^9/L; total bilirubin â‰¤2 times the upper limit of the normal value; alanine aminotransferase and aspartate transaminase (ALT and AST) â‰¤2.5 times the upper limit of the normal value; serum creatinine â‰¤1.5 times the upper limit of the normal value. There is no other treatments (chemotherapy, radiotherapy, etc.) within four weeks before enrollment. There is at least one measurable tumor lesion. Patients have adequate ability to understand, sign informed consents and take part in the clinical research voluntarily. Female patients in child bearing period must have evidence of negative pregnancy test, and agree to take effective contraceptive measures until 4 months after cells infusion. Exclusion Criteria: Patients with two or more kinds of tumors. Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment. Patients with seropositive reponse of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus infection. Patients with active rheumatic diseases, organ transplantation and other diseases affecting the immune system seriously. Patients with severe heart and lung dysfunction. Patients with severe chronic diseases of kidney, liver and other important organs. Patients with any other serious illnesse that the investigators consider it will may affect the patient's treatments, follow-up or assessment, including any uncontrolled clinically significant neurological or psychiatric disorders, immunoregulatory diseases, metabolic diseases, infectious diseases and so on. Patients who take part in clinical trials of other drugs or biological therapy at present or within 30 days before enrollment. Patients who need long-term use of immunosuppressive drugs or patients who are undergoing treatment of autoimmune diseases.Patients who need long-term use of glucocorticoid. Women patients in gestation period or suckling period.", gender: "All", minimum_age: "18 Years", contact_name: "Zhiwei Zhang, Ph.D", contact_phone: "0086-021-39595338", contact_email: "zhangzw@shcell.com")

ArmGroup.create(trial_id: 4, label: "Anti-CTLA-4/PD-1 expressing MUC1-CAR-T", group_type: "Experimental", description: "This study have only one arm that is anti-CTLA-4/PD-1 expressing MUC1-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.", intervention_name: "Biological: Anti-CTLA-4/PD-1 expressing MUC1-CAR-T")

Outcome.create(trial_id: 4, outcome_type: "primary", outcome_measure: "Safety of infusion of autologous CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells", outcome_description: "Determine the toxicity profile of CTLA4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.", outcome_timeframe: "2 years")
Outcome.create(trial_id: 4, outcome_type: "secondary", outcome_measure: "The efficacy of the treatment using CTLA-4 and PD-1 antibodies expressing MUC1-CAR-T cells for advanced solid tumors", outcome_description: "The efficacy of the treatment is assessed according to the response evaluation criteria in solid tumor version 1.1 (RECIST1.1), which is defined as complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD).", outcome_timeframe: "2 years")

Condition.create(trial_id: 4, condition: "Advanced Solid Tumor")
Condition.create(trial_id: 4, condition: "Neoplasms")

Location.create(trial_id: 4, facility: "Ningbo No.5 Hospital (Ningbo Cancer Hospital)", city: "Ningbo", state: "Zhejiang", zip: "315201", country: "United States")

#5 --------------------------------------------
Trial.create(NCTId: "NCT05194709", organization_name: "Wuxi People's Hospital", brief_title: "Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors", official_title: "Clinical Trial of Anti-5T4 Oncofetal Trophoblast Glycoprotein (5T4) Conjugated Antibody Redirecting Natural Killer (CAR-NK) Cells in Advanced Solid Tumors", overall_status: "Recruiting", start_date:  "December 30, 2021", primary_completion_date: "December 30, 2022", primary_completion_date_type: "Anticipated", lead_sponsor: "Wuxi People's Hospital", is_fda_regulated_drug: "No", is_fda_regulated_device: "No", brief_summary: "This study is an interventional, single arm, open-label, investigator-initiated trial (IIT) to evaluate the safety, tolerability, initial efficacy and pharmacokinetics (PK) of anti-5T4 CAR-NK cells in patients with advanced solid tumors.", detailed_description: "The treatment cycle in this study is 21 days. The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle. Subjects will be treated continuously until the criteria for termination of treatment are met. In this study, the dose escalation design is adopted. The first administration dose in the first cycle is 3.0Ã—10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0Ã—10^9 cells, and each administration dose in the second cycle and thereafter would be 4.0Ã—10^9 cells.", study_type: "Interventional", phase: "Phase 1", intervention_type: "Biological", intervention_description: "The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0Ã—10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0Ã—10^9 cells, and each administration dose in the second cycle and thereafter would be 4.0Ã—10^9 cells.", eligibility_criteria: "Inclusion Criteria: Subjects volunteer to participate in this clinical study, are fully aware of the study and have signed the Informed Consent Form (ICF). Subjects are willing to follow and able to complete all trial procedures. Age: adult at the age of 18-80 (both inclusive), female or male. Patients with advanced malignant solid tumors, histologically or cytologically confirmed, who had failed standard therapy, or had no standard therapy, or were not eligible for standard therapy at this stage; tumor biomarkers combined with imaging can be used to diagnose some special advanced tumors. Eastern Cooperative Oncology Group (ECOG) score â‰¤2 and expected survival time >3 months.  Organ function during screening should meet the following criteria: Absolute neutrophil count (ANC)â‰¥0.8Ã—109/L Platelet (PLT)â‰¥50Ã—109/L Hemoglobin (Hb)â‰¥80g/L Total bilirubin (TBIL)â‰¤2Ã—ULN Alanine aminotransferase (ALT)â‰¤3Ã—ULN; Patients with liver metastasis or liver cancer: â‰¤5Ã—ULN Aspartate aminotransferase (AST)â‰¤3Ã—ULN; Patients with liver metastasis or liver cancer: â‰¤5Ã—ULN Creatinine (Cr)â‰¤1.5Ã— ULN Creatinine clearance (Ccr) (to be calculated only when Cr > 1.5Ã— ULN)>50ml/min/1.73m2 (Cockcroft-Gault formula) Activated partial thrombin time (APTT)â‰¤1.5Ã—ULN International normalized ratio (INR)â‰¤1.5Ã—ULN Subjects of reproductive age and their partners should agree to have no family planning and to use effective contraceptive methods (hormonal or barrier methods or abstinence, etc.) for 6 months from signing the ICF until the last dose of the study drug is administered; women of reproductive age should not be pregnant or breastfeeding. Exclusion Criteria: Have received systemic antitumor therapy, including chemotherapy, immunotherapy, and radical radiotherapy, within 1 week prior to their first use of the study drug. Have participated in other clinical trials and received any unmarketed investigational drug or treatment within 4 weeks prior to first use of the study drug. Any prior adoptive cellular immunotherapy. Have undergone major organ surgery (excluding needle biopsy or surgery related to this indication) within 4 weeks prior to their first use of the study drug, or required elective surgery during the study period. Patients with severe infections that cannot be controlled. Patients with a known history of human immunodeficiency virus (HIV) infection, or a history of organ transplantation. Have active autoimmune diseases or have had autoimmune diseases that are likely to recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, vasculitis, psoriasis, etc.). Except in the following cases: type 1 diabetes that was well controlled with hormone replacement therapy, hypothyroidism, skin conditions that did not require systemic therapy (e.g., vitiligo), and other conditions that were well controlled and that the investigator determined were less likely to recur (e.g., childhood asthma in remission). Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to: There are serious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia, and â…¡-â…¢ degree atrioventricular block, which need clinical intervention; The mean QT interval corrected by Fridericia method (QTcF) is prolonged (male>450ms, female>470ms); Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or above cardiovascular and cerebrovascular events occurring within 6 months before the first administration; Patients with heart failure or left ventricular ejection fraction (LVEF) < 50% in the New York Heart Association (NYHA) classification â‰¥II; Hypertension beyond clinical control. Adverse effects of previous antineoplastic therapy have not returned to CTCAE grade 5.0â‰¤2 (except for toxicity that the investigator determined to be of no safety risk, such as alopecia, hypothyroidism stabilized by hormone replacement therapy). Central nervous system metastases with clinical symptoms. Had other malignant tumors in the past 3 years, excluding skin basal cell carcinoma, ductal carcinoma in situ and cervical carcinoma in situ with a radical surgery. Have a history of alcohol or drug abuse or mental disorder. The investigator considered that the subjects had a history of other serious systemic diseases or other reasons that made them unsuitable for the study.", gender: "All", minimum_age: "18 Years", contact_name: "Peihua Lu, MD", contact_phone: "+8613583991399", contact_email: "lyzlyylxm@163.com")

ArmGroup.create(trial_id: 5, label: "Anti-5T4 CAR-NK Cells", group_type: "Experimental", description: "N/A", intervention_name: "Biological: Anti-CAR-NK Cells")

Outcome.create(trial_id: 5, outcome_type: "primary", outcome_measure: "Number of Adverse Events (AEs)", outcome_description: "To evaluate the safety and tolerability of anti-5T4 CAR-NK cells", outcome_timeframe: "From day 1 to day 90 after the last dose")
Outcome.create(trial_id: 5, outcome_type: "secondary", outcome_measure: "Objective response rate (ORR)", outcome_description: "To determine the anti-tumor effectivity of anti-5T4 CAR-NK cells", outcome_timeframe: "Up to 1 year after infusion")
Outcome.create(trial_id: 5, outcome_type: "secondary", outcome_measure: "Progression-free survival (PFS)", outcome_description: "To determine the anti-tumor effectivity of anti-5T4 CAR-NK cells", outcome_timeframe: "Up to 1 year after infusion")
Outcome.create(trial_id: 5, outcome_type: "secondary", outcome_measure: "Overall survival (OS)", outcome_description: "To determine the anti-tumor effectivity of anti-5T4 CAR-NK cells", outcome_timeframe: "Up to 1 year after infusion")
Outcome.create(trial_id: 5, outcome_type: "secondary", outcome_measure: "Disease control rate (DCR)", outcome_description: "To determine the anti-tumor effectivity of anti-5T4 CAR-NK cells", outcome_timeframe: "Up to 1 year after infusion")
Outcome.create(trial_id: 5, outcome_type: "secondary", outcome_measure: "Cytokine release", outcome_description: "Blood samples will be collected at specified time points to detect the cytokine (IL-1Î², IL-2, IL-4, IL-6, IL-10, IFN-Î³, hsCRP) concentration (pg/mL)", outcome_timeframe: "Up to 1 year")
Outcome.create(trial_id: 5, outcome_type: "secondary", outcome_measure: "Lymphocyte subtype", outcome_description: "Blood samples will be collected at specified time points to analyze the lymphocyte subtypes (CD3, CD4, CD8, CD19, CD56)", outcome_timeframe: "Up to 1 year")

Condition.create(trial_id: 5, condition: "Neoplasms")
Condition.create(trial_id: 5, condition: "Advanced Solid Tumors")

Location.create(trial_id: 5, facility: "Wuxi People's Hospital", city: "Wuxi", state: "Jiangsu", zip: "N/A", country: "China")

#6 --------------------------------------------
Trial.create(NCTId: "NCT01818323", organization_name: "King's College London", brief_title: "Phase I Trial: T4 Immunotherapy of Head and Neck Cancer", official_title: "Phase I Trial: T4 Immunotherapy of Head and Neck Cancer", overall_status: "Completed", start_date: "June 2015", primary_completion_date: "December 2023", primary_completion_date_type: "Anticipated", lead_sponsor: "King's College London", is_fda_regulated_drug: "No", is_fda_regulated_device: "No", brief_summary: "The overall goal of this study is to investigate the safety of T4 immunotherapy when administered to treat loco-regional disease in Squamous Cell Cancer of the Head and Neck (SCCHN) that is not suitable for conventional active therapy. The investigators propose to conduct an open-labelled, non-randomized, dose-escalation phase I trial in which autologous T4+ T-cells are administered to patients with SCCHN. T-cells will be engineered to express a second generation chimeric antigen receptor (CAR) named T1E28z. Engineered T-cells will be injected directly into the tumour site. Patients will not be lymphodepleted. A classical 3+3 design will be employed, with dose escalation from 10^7 through to 10^9 transduced T4+ T-cells, dependent upon toxicity monitoring. It is anticipated that up to 30 patients will be enrolled over the course of the study.", detailed_description: "Further information is provided in van Schalkwyk MC, Papa SE, Jeannon JP, Guerrero Urbano T, Spicer JF, Maher J. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev. 2013 Sep;24(3):134-42. doi: 10.1089/humc.2013.144. PubMed ID: 24099518", study_type: "Interventional", phase: "Phase 1", intervention_type: "Other", intervention_description: "Intra-tumoral administration of a single dose of T4-positive patient-derived T-cells (at five escalating dose levels) contained within 1-4 mL. Cohort 6 patients receive CAR T-cells (dose level 3) after lymphodepletion with fludarabine and cyclophosphamide", eligibility_criteria: "Inclusion Criteria: Histologically and/ or cytologically confirmed SCCHN. 18 years or older. Locally advanced and/ or recurrent head and neck cancer with or without metastatic disease (excluding brain metastases) for whom no standard therapy remains or is suitable. Regarding previous treatment, patients may have received prior systemic therapy, including platinum chemotherapy, at least one month earlier. In the presence of metastatic disease, recent short-course palliative radiotherapy to non-target site(s) is allowed. Those who refuse palliative treatment may be eligible for participation. However, their reasons for not opting for palliative treatment must be explored thoroughly. At least one loco-regional target lesion measurable by RECIST v1.1 criteria on CT or MRI scanning within four weeks of enrolment, and amenable to intra-tumoral injection. Eastern Co-operative Oncology Performance Status of 0-2. Normal cardiac function as assessed by electrocardiography and either echocardiography (ECHO), or multi-gated acquisition (MUGA) scanning. Left ventricular ejection fraction must be > 50%. Assessment must take place within four weeks of enrolment. Haematology results within seven days of enrolment: neutrophils >1.5 x 109/L, platelets >100 x 109/L, haemoglobin >9g/dl, INR <1.5. Biochemistry results within seven days of enrolment: â€¢ serum creatinine <1.5 upper limit of normal â€¢ bilirubin <1.25 times normal; â€¢ ALT/ AST <2.5 times upper limit of normal (<5 times upper limit of normal if liver metastases present) Female patients must be postmenopausal (12 months of amenorrhea), surgically sterile or they must agree to use a physical method of contraception. Oral or injectable contraceptive agents cannot be the sole method of contraception. Women of childbearing potential (WOCB) who receive cyclophosphamide must adhere to these contraceptive requirements during the trial and until 3 months after the last dose of cyclophosphamide. Male patients, even if sterilized, must agree to use a barrier method of contraception. Male subjects must also commit to use a barrier method of contraception until at least 3 months after the end of study treatment. Written informed consent prior to registration. Eligible for NHS care in the UK. Exclusion Criteria: The presence of or imminent occurrence of airway obstruction, unless tracheostomy in place. The presence of or imminent occurrence of tumour-mediated infiltration of major blood vessels. Positive history of HIV-1, HIV-2, HTLV-1, HTLV-2, Hepatitis B, Hepatitis C or syphilis infection. Prior splenectomy. Clinically active autoimmune disease. Sub-clinical or quiescent autoimmune disease does not exclude from participation. Treatment in the preceding week with systemic corticosteroids (> 20mg prednisolone/ day), any systemic immunomodulatory agent, radiotherapy, chemotherapy or investigational medicinal product. Concurrent use of anticoagulant therapy is not permissible. The presence of major co-morbidity likely to impair ability to undergo trial therapy, such as recent myocardial infarction, congestive cardiac failure or uncontrolled hypertension. The presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. Cyclophosphamide allergy (Cohort 6 only). Pregnancy. Breastfeeding. Prior T4 immunotherapy.", gender: "All", minimum_age: "18 Years", contact_name: "John Maher, MD PhD", contact_phone: "(+44) 02071881468", contact_email: "john.maher@kcl.ac.uk")

ArmGroup.create(trial_id: 6, label: "Intra-tumoral T4 immunotherapy", group_type: "Experimental", description: "Treatment arms comprise escalating doses of T4 immunotherapy, administered alone or in combination with lymph-depleting chemotherapy", intervention_name: "Other: Intra-tumoral T4 immunotherapy")

Outcome.create(trial_id: 6, outcome_type: "primary", outcome_measure: "Dose limiting toxicities for T4 immunotherapy in SCCHN and determine a safe and feasible recommended dose for phase II testing of intra-tumoral T4 immunotherapy.", outcome_description: "Patients will be monitored intensely for the first 24 hours post T4 administration. Patients will the be assessed for signs of toxicity on days 3-4, 5-7, 8, 15, 29 and 43.", outcome_timeframe: "Up to 6 weeks post T4 administration")
Outcome.create(trial_id: 6, outcome_type: "secondary", outcome_measure: "To investigate serum cytokine levels after administration of T4 immunotherapy", outcome_description: "", outcome_timeframe: "Up to 6 weeks post T4 administration")
Outcome.create(trial_id: 6, outcome_type: "secondary", outcome_measure: "To investigate persistence of T4+ T-cells at the site of administration and in the peripheral circulation", outcome_description: "", outcome_timeframe: "Up to 6 weeks post T4 administration")
Outcome.create(trial_id: 6, outcome_type: "secondary", outcome_measure: "To achieve preliminary assessment of anti-tumour activity, using cross-sectional imaging to quantify objective responses", outcome_description: "", outcome_timeframe: "Up to 6 weeks post T4 administration")
Outcome.create(trial_id: 6, outcome_type: "secondary", outcome_measure: "To investigate tumour ErbB receptor phenotype, before and after administration of T4 immunotherapy", outcome_description: "", outcome_timeframe: "Up to 6 weeks post T4 administration")
Outcome.create(trial_id: 6, outcome_type: "secondary", outcome_measure: "To investigate immunomodulatory effects of metronomic cyclophosphamide on T4 immunotherapy", outcome_description: "Pre- and post-treatment absolute number of circulating T-regulatory cells will be compared.", outcome_timeframe: "Up to 6 weeks post T4 administration") 
Outcome.create(trial_id: 6, outcome_type: "secondary", outcome_measure: "To investigate effect of T4 immunotherapy upon immune reactivity against endogenous tumour antigens", outcome_description: "ELISPOT will be performed on blood samples taken 3 days prior and 29 days after T4 administration to measure for MAGE-reactive T-cells.", outcome_timeframe: "Up to 6 weeks post T4 administration") 

Condition.create(trial_id: 6, condition: "Head and Neck Cancer")

Location.create(trial_id: 6, facility: "Clinical Research Facility, Guy's Hospital", city: "London", state: "N/A", zip: "SE1 9RT", country: "United Kingdom")

#7 --------------------------------------------
Trial.create(NCTId: "NCT03851146", organization_name: "Peter MacCallum Cancer Centre, Australia", brief_title: "A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours", official_title: "A Phase I Investigation of the Safety, Tolerability and Immunological Effects of T Lymphocytes Transduced With an Anti-Lewis Y (LeY) Chimeric Antigen Receptor Gene (LeY-CAR-T) in Patients With LeY Antigen Expressing Advanced Solid Tumours", overall_status: "Completed", start_date: "November 24, 2016", primary_completion_date: "April 1, 2022", primary_completion_date_type: "Actual", lead_sponsor: "Peter MacCallum Cancer Centre, Australia", is_fda_regulated_drug: "No", is_fda_regulated_device: "No", brief_summary: "This clinical trial is an open-label, single-centre, phase I study designed to investigate the safety and tolerability of a single infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-Î¶ vector (LeY CAR T-cells) The primary aim of the trial is to evaluate the safety and tolerability of LeY CAR T cells in patients with Lewis Y antigen-expressing, advanced solid tumours. The secondary aim of the trial is to assess the anti-tumour activity of LeY CAR T cells in patients with LeY antigen-expressing, advanced solid tumours. Patients aged 18 years or older with advanced solid tumours have consented to pre-screening that allows their tumours to be assessed for LeY expression by immunohistochemistry. Patients whose tumours test positive for LeY were then able to proceed to eligibility screening and, if found to fulfil the eligibility criteria, were registered in the study. The study involves an initial dose escalation phase followed by an expansion phase.", detailed_description: "To autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-Î¶ vector in patients with LeY expressing advanced solid tumours. evaluate the safety and tolerability of an intravenous infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-Î¶ vector in patients with LeY expressing advanced solid tumours. Aims: To evaluate the safety and tolerability of an intravenous infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-Î¶ vector in patients with LeY expressing advanced solid tumours. Primary Objectives To determine the maximum tolerated dose and rate of dose limiting toxicities of a single intravenous infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-Î¶ vector in patients with LeY expressing advanced solid tumours (LeY CAR T cells). Secondary Objectives i. To assess the anti-tumour activity of the LeY CAR T cells in terms of overall response, duration of response, progression free survival and overall survival. ii. To assess persistence in peripheral blood of the LeY CAR T cells. The study will recruit an anticipated number of 12 patients in the dose escalation phase consisting of 4 dose levels, each with dose level cohorts of 3 patients. Following completion of the dose-escalation phase, additional patients with Le Y expressing solid tumours will be recruited to the study. These patients will be administered the maximum number of cells safely delivered in the dose escalation phase of the study. A subset comprising 5 patients in the expansion cohort will be administered Indium-111 labelled T-cells and imaged by SPECT to determine the biodistribution of reinfused T cells. If the proposed number of T cells is unable to be obtained due to technical production reasons, the available number will be infused. It is anticipated that up to 30 patients will be treated on this protocol.", study_type: "Interventional", phase: "Phase 1", intervention_type: "Biological", intervention_description: "Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-Î¶ vector (LeY CAR T cells)", eligibility_criteria: "Inclusion Criteria: All of the following must apply at the time of enrollment: Patients with an advanced solid tumour (defined as incurable locally advanced or metastatic disease and excluding any haematologic malignancy). Tumour is positive for Lewis Y expression by immunohistochemistry - defined as a staining of â‰¥ 10 % of tumour cells positive for LeY expression. For the purposes of tumour screening, where possible the most recently available tumour sample should be utilised. A new biopsy is not mandatory where archival tissue is available, but may be considered. Patient is â‰¥18 years of age.Patient has an ECOG performance status of 0 - 1 Patient has provided written confirmation of informed consent on participant information and consent form Life expectancy of â‰¥ 12 weeks Patient has adequate organ function satisfying all of the following: Liver: bilirubin <1.5x upper limit of normal (ULN) unless patient has known Gilbert's syndrome; AST/ALT â‰¤2.5 x ULN except in patients with known liver metastases where AST/ALTâ‰¤5.0 Kidney: either serum creatinine <1.5x ULN or creatinine clearance > 50ml/min. Creatinine clearance is either derived using the Cockcroft-Gault formula or may be measured by 24 hour urine collection or nuclear medicine assessment. Lung: Adequate pulmonary function defined by SaO2 >91% on room air and â‰¤ grade I dyspnoea. Cardiac: LVEF â‰¥ 40% as confirmed by echocardiogram or multiple uptake gated acquisition (MUGA) Adequate bone marrow reserve as defined as: Absolute neutrophil count (ANC) â‰¥ 1.0 x 10e9/L Absolute lymphocyte count â‰¥ 0.5 x 10e9/L Platelets â‰¥ 100 x 10e9/L Haemoglobin >80g/L WCC <30 x 10e9/L Patient is deemed capable and willing to undergo the planned study procedures in the view of the principal investigator. Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants must agree to use highly effective methods of contraception for one year following LeY CART therapy. Patient has measurable disease as per RECIST 1.1. Exclusion Criteria: Patients who meet any of the following criteria will be excluded from participation in this study: Patients with known active central nervous system (CNS) involvement by malignancy. Patients with previous treated and/or neurologically stable disease will be eligible. Prior chimeric antigen receptor T (CART) cell therapy Patient has been given chemotherapy and/or G-CSF in the last 4 weeks or is planned to receive such therapy prior to apheresis of PBMC. Patients can only receive cytotoxic drugs as per the schedule of treatment for this protocol. Patient has had immunosuppressive therapy within 4 weeks of apheresis. Therapeutic doses of steroids (defined as > 20 mg/day of Prednisolone (or equivalent) must be able to be stopped > 7 days prior to leukapheresis and 72 hours prior to LeY CART cell infusion Physiologic doses of steroid (e.g. Prednisolone <10mg or equivalent), topical and inhaled steroids are permitted. Patient who are eligible for potentially curative therapy Uncontrolled active or latent Hepatitis B or active Hepatitis C or HIV Patients with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics. History or presence of active clinically relevant CNS pathology such as epilepsy, aphasia, severe brain injury, dementia, Parkinson's disease, cerebellar disease or psychosis.Radiation therapy within 2 weeks prior to registration Patient has an active haematologic malignancy (any lymphoma, leukaemia, multiple myeloma or myelodysplastic syndrome) Patient has a history of significant pulmonary disease (including radiation pneumonitis) or known, biopsy proven autoimmune inflammatory disease of the gastrointestinal tract. Unstable angina or myocardial infarct within 6 months prior to screening. Patient has known clinically significant autoimmune disease with positive serology for RHF (>20kU/L) or ANA (titre >1:40). Women of child bearing potential (WOCBP) who are unwilling or unable to use an effective method of contraception to avoid pregnancy for the entire study period and for at least 12 months after completion of study treatment. Women who are pregnant or breastfeeding. Men who are unwilling or unable to use an acceptable method of contraception for the entire study period and for at least 12 months after completion of study treatment if their sexual partners are WOCBP. Patient has a serious uncontrolled medical disorder, psychological or social factors that which would impair the ability to receive protocol therapy and follow up.", gender: "All", minimum_age: "18 Years", contact_name: "Ben Solomon", contact_phone: "", contact_email: "")

ArmGroup.create(trial_id: 7, label: "LeY CAR T cells", group_type: "Experimental", description: "One arm study consisting of '3 + 3' dose escalation study design (see below) followed by dose expansion phase at determined MTD. Dose level : Target Number LeY CART cells infused *-1 (if needed): 1 x 10e8 2 x 10e8 5 x 10e8 1 x 10e9 5 x 10e9 Targeted number of LeY CAR T cells (minus 40% acceptance range) for manufacture according toTGA-approved standard protocolsTreatment follows a lymphodepleting, chemotherapy regimen that consists of Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 consecutive days prior to cell infusion, with chemotherapy completed at least 48 hours before the re-infusion of the LeY CAR T cells.", intervention_name: "Biological: LeY CAR T cells")

Outcome.create(trial_id: 7, outcome_type: "primary", outcome_measure: "The Maximum Tolerated Dose (MTD) of LeY CAR T-cell infusion", outcome_description: "To determine the maximum tolerated dose of a single intravenous infusion of Le Y CAR T-cells in patients with LeY expressing advanced solid tumours.This outcome will be assessed by evaluating occurrence, type, severity and relationship to treatment of adverse events (AEs) according to NCI CTCAE v4.03 and laboratory abnormalities. To be reported as Total Number of Le Y CAR T-cells infused eg. Y x 10e(9)", outcome_timeframe: "4 weeks")
Outcome.create(trial_id: 7, outcome_type: "secondary", outcome_measure: "The Dose-Limiting Toxicities (DLTs) associated with LeY CAR T-cell infusion", outcome_description: "To determine the rate of dose limiting toxicities of a single intravenous infusion of Le Y CAR T-cells in patients with LeY expressing advanced solid tumours. DLT Definition: Any treatment-emergent Grade 4 or 5 (death) AEs related to LeY CAR T cells, excluding laboratory values deemed not clinically significant. Any treatment-emergent Grade 3 AEs related to LeY CAR T cells that do not resolve to â‰¤ Grade 2 within 7 days, excluding laboratory values deemed not clinically significant Any treatment-emergent Grade 3 or 4 seizure Any treatment-emergent autoimmune event â‰¥ Grade 3. All Adverse Events(AEs) will recorded in the eCRF using the severity grade according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.", outcome_timeframe: "4 weeks")
Outcome.create(trial_id: 7, outcome_type: "secondary", outcome_measure: "To assess the Overall Response (OR) to anti-tumour activity of LeY CAR T-cells", outcome_description: "Overall response (OR), defined as the best response to the CAR T-cells re-infusion based on RECIST v1.1 criteria. Response will be determined by CT scan at baseline (screening), week 4 and week 8 post-infusion, every 8 weeks thereafter until 1 year has elapsed, followed by every 12 weeks until progression. The main analysis will occur once all patients have had 12 months follow up with the final analysis to occur once all patients have had 5 years follow-up.", outcome_timeframe: "5 years")
Outcome.create(trial_id: 7, outcome_type: "secondary", outcome_measure: "To assess the Duration of Response (PR) to anti-tumour activity of LeY CAR T-cells", outcome_description: "Duration of response, defined as the time from the date of first response of PR or better until the date of disease progression, for those patients who experience a PR or better as assessed by RECIST v1.1 criteria (death is a censoring event), for those patients who experience a PR or better. Response will be determined by CT scan at baseline (screening), week 4 and week 8 post-infusion, every 8 weeks thereafter until 1 year has elapsed, followed by every 12 weeks until progression. The main analysis will occur once all patients have had 12 months follow up with the final analysis to occur once all patients have had 5 years follow-up.", outcome_timeframe: "5 years")
Outcome.create(trial_id: 7, outcome_type: "secondary", outcome_measure: "To assess the Progression Free Survival (PFS) of patients treated with LeY CAR T-cells", outcome_description: "Progression free survival (PFS), defined as the time from LeY CAR T cells re-infusion to the earliest of date of disease progression as assessed by RECIST v1.1criteria or death. Response will be determined by CT scan at baseline (screening), week 4 and week 8 post-infusion, every 8 weeks thereafter until 1 year has elapsed, followed by every 12 weeks until progression. The main analysis will occur once all patients have had 12 months follow up with the final analysis to occur once all patients have had 5 years follow-up.", outcome_timeframe: "5 years")
Outcome.create(trial_id: 7, outcome_type: "secondary", outcome_measure: "To assess the Overall Survival (OS) of patients treated with LeY CAR T-cells", outcome_description: "Overall survival (OS), defined as the time from LeY CAR T cells re-infusion to date of death.\n\nResponse will be determined by CT scan at baseline (screening), week 4 and week 8 post-infusion, every 8 weeks thereafter until 1 year has elapsed, followed by every 12 weeks until progression.\n\nThe main analysis will occur once all patients have had 12 months follow up with the final analysis to occur once all patients have had 5 years follow-up.", outcome_timeframe: "5 years")

Condition.create(trial_id: 7, condition: "Advanced Cancer")

Location.create(trial_id: 7, facility: "Peter MacCallum Cancer Centre", city: "Melbourne", state: "Victoria", zip: "3000", country: "Australia")

#8 --------------------------------------------
Trial.create(NCTId: "NCT05554276", organization_name: "Shanghai Jiao Tong University Affiliated Sixth People's Hospital", brief_title: "Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer", official_title: "Neoadjuvant Chemotherapy Combined With PD-1 Antibody + Radical Radiotherapy in Unresectable Locally Advanced Cervical Cancer Patients", overall_status: "Not yet recruiting", start_date: "October 1, 2022", primary_completion_date: "January 31, 2025", primary_completion_date_type: "Anticipated", lead_sponsor: "Shanghai Jiao Tong University Affiliated Sixth People's Hospital", is_fda_regulated_drug: "No", is_fda_regulated_device: "No", brief_summary: "Based on various external factors and differences in the basic characteristics of patients, in my country, it is not clear whether concurrent chemoradiotherapy can achieve optimal therapeutic effect in patients with pathologically diagnosed stage IIB or above locally advanced cervical cancer. Under the limitations of radiotherapy and surgery conditions in the region, some patients will try neoadjuvant chemotherapy combined with PD-1 antibody therapy before standard radiotherapy, hoping to reduce cancer focus and reduce infiltration. Thereby reducing the scope of radiotherapy, better ensure the efficacy of late radiotherapy and chemotherapy and reduce the side effects of radiotherapy. Judging from the review of such patients, neoadjuvant chemotherapy combined with PD-1 antibody therapy + radical radiotherapy seems to have certain efficacy and tolerance in the near future as expected. No statistical analysis has been done on the long-term survival of patients. This topic intends to treat inoperable locally advanced cervical cancer patients with neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy, and explore the treatment-related toxic and side effects and efficacy of neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy. It is hoped that through this study, it will provide a reference for the comprehensive treatment of inoperable locally advanced cervical cancer that has been pathologically diagnosed in the future.", detailed_description: "Based on various external factors and differences in the basic characteristics of patients, in my country, it is not clear whether concurrent chemoradiotherapy can achieve optimal therapeutic effect in patients with pathologically diagnosed stage IIB or above locally advanced cervical cancer. Under the limitations of radiotherapy and surgery conditions in the region, some patients will try neoadjuvant chemotherapy combined with PD-1 antibody therapy before standard radiotherapy, hoping to reduce cancer focus and reduce infiltration. Thereby reducing the scope of radiotherapy, better ensure the efficacy of late radiotherapy and chemotherapy and reduce the side effects of radiotherapy. Judging from the review of such patients, neoadjuvant chemotherapy combined with PD-1 antibody therapy + radical radiotherapy seems to have certain efficacy and tolerance in the near future as expected. No statistical analysis has been done on the long-term survival of patients. This topic intends to treat inoperable locally advanced cervical cancer patients with neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy, and explore the treatment-related toxic and side effects and efficacy of neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy. It is hoped that through this study, it will provide a reference for the comprehensive treatment of inoperable locally advanced cervical cancer that has been pathologically diagnosed in the future.", study_type: "Interventional", phase: "Phase 2", intervention_type: "Combination Product", intervention_description: "All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.", eligibility_criteria: "Inclusion Criteria: Patients who were pathologically diagnosed with cervical squamous cell carcinoma and were assessed as unresectable. Exclusion Criteria: Any active or present autoimmune disease (eg, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism)", gender: "Female", minimum_age: "18 Years" , contact_name: "", contact_phone: "", contact_email: "")

ArmGroup.create(trial_id: 8, label: "neoadjuvant chemotherapy+ PD-1 antibody + radical radiotherapy", group_type: "Experimental", description: "All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.", intervention_name: "Combination Product: neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy")

Outcome.create(trial_id: 8, outcome_type: "primary",outcome_measure: "Objective Response Rate", outcome_description: "refers to the proportion of patients whose tumors shrink to a certain amount and maintain for a certain period of time (4 weeks after all treatments), including CR+PR cases. CR (complete remission): disappearance of all target lesions, PR (partial remission): reduction of the sum of the length and diameter of the baseline lesions by â‰¥30%", outcome_timeframe: "4 weeks after all treatments")
Outcome.create(trial_id: 8, outcome_type: "secondary",outcome_measure: "Safety", outcome_description: "incidence of treatment acute AEs, radiation enteritis, radiation cystitis", outcome_timeframe: "during the procedure")
Outcome.create(trial_id: 8, outcome_type: "secondary",outcome_measure: "DFS", outcome_description: "year 1 and year 5 DFS", outcome_timeframe: "year 1 and year 5")
Outcome.create(trial_id: 8, outcome_type: "secondary",outcome_measure: "OS", outcome_description: "year 1 and year 5 OS", outcome_timeframe: "year 1 and year 5")

Condition.create(trial_id: 8, condition: "Uterine Cervical Neoplasms")
Condition.create(trial_id: 8, condition: "Cervical Cancer")

Location.create(trial_id: 8, facility: "Emory University Hospital", city: "Atlanta", state: "Georgia", zip: "30322", country: "United States")

#9 --------------------------------------------
Trial.create(NCTId: "NCT04792593", organization_name: "Hebei Senlang Biotechnology Inc., Ltd.", brief_title: "Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia", official_title: "Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia", overall_status: "Unknown status", start_date: "December 3, 2020", primary_completion_date: "February 10, 2022", primary_completion_date_type: "Anticipated", lead_sponsor: "Hebei Senlang Biotechnology Inc., Ltd.", is_fda_regulated_drug: "No", is_fda_regulated_device: "No", brief_summary: "This study is an open, dose-escalating clinical study, taking patients with relapsed or refractory acute lymphoblastic leukemia as the test subjects, including mouse-derived CAR-T treatment failure or relapse, or for any reason cannot bridge the transplant r/r B-ALL.", detailed_description: "Main research objectives: To evaluate the safety and efficacy of Senl-h19 CAR-T in patients with relapsed or refractory acute lymphoblastic leukemia Secondary research purpose To investigate the cytokinetic characteristics of Senl-h19 CAR-T in patients with relapsed or refractory acute lymphoblastic leukemia.", study_type: "Interventional", phase: "N/A", intervention_type: "Biological", intervention_description: "Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis", eligibility_criteria: "Inclusion Criteria: 1. Sign the informed consent and be willing and able to comply with the visit, treatment protocol, laboratory examination, and other requirements of the study as specified in the study procedure sheet; 2. A definite diagnosis of relapsed and refractory acute B-lymphoblastic leukemia meets one of the following criteria: a) Mouse CAR-T treatment fails or relapses; B) Unable to bridge the graft for any reason; 3. Eastern Cooperative Oncology Group (ECOG) score â‰¤2; 4. Age â‰¥2 years old, male or female 5. CD19 positive tumor cells were detected by immunohistochemistry or flow cytometry; 6. Expected survival longer than 3 months; 7. The collection time of peripheral blood mononuclear immune cells must be at least 2 weeks from the last radiotherapy or systematic treatment of patients; Exclusion Criteria: 1. Severe cardiac insufficiency; 2. Have a history of severe lung impairment; 3. Complicated with other advanced malignant tumors; 4. Complicated with severe or persistent infection that cannot be effectively controlled; 5. Complicated with severe autoimmune diseases or congenital immune deficiency; 6. Active hepatitis (HBVDNA or HCVRNA positive); Human immunodeficiency virus (HIV) infection or syphilis infection; 8. Have a history of severe allergy to biological products (including antibiotics); 9. The female patient is pregnant and lactating, or has a pregnancy plan within 12 months; 10. Conditions that the investigator believes may increase the risk to the subject or interfere with the outcome of the study.", gender: "All", minimum_age: "2 Years", contact_name: "Peihua MD Lu, PhD", contact_phone: "008618611636172", contact_email: "peihua_lu@126.com")

ArmGroup.create(trial_id: 9, label: "Senl-h19 CAR-T", group_type: "Experimental", description: "Patients will be treated with Senl-h19 CAR-T cells", intervention_name: "Biological: Senl-h19 CAR-T")

Outcome.create(trial_id: 9, outcome_type: "primary", outcome_measure: "Safety: Incidence and severity of adverse events", outcome_description: "To evaluate the possible adverse events occurred within first one month after CD7 CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity", outcome_timeframe: "First 1 month post CAR-T cells infusion")
Outcome.create(trial_id: 9, outcome_type: "primary", outcome_measure: "Efficacy: Remission Rate", outcome_description: "Remission Rate including complete remission(CR)ã€CR with incomplete blood count recovery(CRi)ã€No remission(NR)", outcome_timeframe: "3 months post CAR-T cells infusion")
Outcome.create(trial_id: 9, outcome_type: "secondary", outcome_measure: "duration of response (DOR)", outcome_description: "duration of response (DOR)", outcome_timeframe: "24 months post CAR-T cells infusion")
Outcome.create(trial_id: 9, outcome_type: "secondary", outcome_measure: "progression-free survival (PFS)", outcome_description: "progression-free survival (PFS) time", outcome_timeframe: "24 months post CAR-T cells infusion")
Outcome.create(trial_id: 9, outcome_type: "secondary", outcome_measure: "CAR-T proliferation", outcome_description: "the copy number of Senl h19 CAR- T cells in the genomes of PBMC by qPCR method", outcome_timeframe: "3 months post CAR-T cells infusion")
Outcome.create(trial_id: 9, outcome_type: "secondary", outcome_measure: "Cytokine release", outcome_description: "Cytokine( IL-6,IL-10,IFN-Î³,TNF-Î± ) concentration (pg/mL) by flow cytometry method", outcome_timeframe: "First 1 month post CAR-T cells infusion")

Condition.create(trial_id: 9, condition: "Precursor Cell Lymphoblastic Leukemia-Lymphoma")
Condition.create(trial_id: 9, condition: "Leukemia, Lymphoid")

Location.create(trial_id: 9, facility: "Hebei yanda Ludaopei Hospital", city: "Yanda", state: "Hebei", zip: "N/A", country: "China")

#10 --------------------------------------------
Trial.create(NCTId: "NCT03615313", organization_name: "Shanghai Cell Therapy Research Institute", brief_title: "PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor", official_title: "A Clinical Study of PD-1 Antibody Expressing mesoCAR-T Cells for Patients With Mesothelin Positive Advanced Solid Tumors", overall_status: "Unknown status", start_date: "August 6, 2018", primary_completion_date: "August 3, 2020", primary_completion_date_type: "Anticipated", lead_sponsor: "Shanghai Cell Therapy Research Institute", is_fda_regulated_drug: "No", is_fda_regulated_device: "No", brief_summary: "This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to target mesothelin and express PD-1 antibodies in adult patients with advanced recurrent or refractory malignant solid tumors, which were positive expression of mesothelin.", detailed_description: "This study will be conducted using a phase I/II trial design to assess the safety and efficacy of the PD-1 antibody expressing mesoCAR-T for patients with mesothelin positive, advanced recurrent or refractory malignant solid tumors. MesoCAR-T can specifically and effectively kill the mesothelin positive cancer cells, PD-1 antibody are secreted from the CAR-T cells could improve immunosuppression microenvironment, new CAR-T cells contain the advantages of CAR-T and immune checkpoint inhibitor, which is a promising therapeutic method for advanced solid tumors. The new CAR-T therapy is applied to clinical practice as bellow. T cells are prepared from peripheral blood mononuclear cells (PBMC) by leukapheresis, and then activated and engineered to express chimeric antigen receptors (CARs) targeting mesothelin and PD-1 antibody. Cells are proliferated in culture and returned to the patients by venous transfusion therapy. A total of 50 patients may be enrolled in the study. The total duration of the study is expected to be approximately 24 months.", study_type: "Interventional", phase: "Phase 1", intervention_type: "Biological", intervention_description: "Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.", eligibility_criteria: "Inclusion Criteria: Patients with relapsed or refractory advanced solid malignancies (diagnosed by histology or cytology detection), including malignant mesothelioma, pancreatic cancer, bile duct cancer, ovarian cancer, lung cancer, gastric cancer, etc. Patients who failed after second-line treatment, or who are unwilling to receive second-line treatment after failed to recieve first-line treatment. Gender unlimited, age from 18 years to 80 years. Life expectancy â‰¥ 3 months. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Adequate venous access for Peripheral blood mononuclear cell (PBMC) apheresis, and no other contraindications. Immunohistochemistry (IHC) score of mesothelin on tumor tissue â‰¥ 1+. The requirements of laboratory examination: Neutrophilic granulocyte â‰¥ 1.0Ã—10^9/L; Platelet â‰¥ 50Ã—10^9/L; Hemoglobin â‰¥ 90g/L; total bilirubin â‰¤ 2 times the upper limit of the normal value; Alanine aminotransferase and Aspartate transaminase (ALT and AST) â‰¤ 2.5 times the upperlimit of the normal value (If there is liver metastasis, they should be â‰¤ 5 times the upperlimit of the normal value); Serum creatinine â‰¤ 1.5 times the upper limit of the normalvalue. There is at least one measurable tumor lesion; According to RECIST 1.1 standard, it is suitable to evaluate the therapeutic response and progress of tumor. Patients have adequate ability to understand, sign informed consents and take part in the clinical research voluntarily. Female patients in child bearing period must have evidence of negative pregnancy test or male patients, and they agree to take effective contraceptive measures until 30 days after cells infusion. Exclusion Criteria: Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment. Patients with seropositive response of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus infection. Patients who are undergoing treatment of autoimmune or organ transplantation diseases, or patients who need long-term use of immunosuppressive drugs such as glucocorticoid. Patients with severe heart and lung dysfunction, high blood pressure and cannot be controlled with medicine, unstable coronary artery disease (uncontrolled arrhythmias, unstable angina pectoris), uncompensated congestive heart failure, myocardial infarction within six months. Patients with any other illness that the investigators consider it will may affect the patient's treatments, follow-up or assessment, including any uncontrolled clinically significant neurological or psychiatric disorders, immunoregulatory diseases, metabolic diseases, infectious diseases and so on. Received cancer treatment prior to enroll the group within the following time (including drug clinical trials): (1) The withdrawal time of chemotherapy before enrollment was shorter than the treatment cycle of chemotherapy. (2) The use of anti-tumor therapy within 4 weeks before the study or less than 5 times of the half-life period of the drugs (including radiation therapy, chemotherapy, small molecules and biological therapy or immunotherapy), the shortest period of time was as the criterion (but the shortest time should not be less than 21 days). 7. Women patients in pregnancy period or suckling period.", gender: "All", minimum_age: "18 Years", contact_name: "Zhiwei Zhang, PhD", contact_phone: "0086-021-59593168", contact_email: "zhangzw@shcell.com")

ArmGroup.create(trial_id: 10, label: "PD-1 antibody expressing mesoCAR-T cells", group_type: "Experimental", description: "Patients will receive two cycles of PD-1 antibody expressing mesoCAR-T cells treatment. Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day -18, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of PD-1 antibody expressing mesoCAR-T cells from day 1 to day 3 (Â±3days).", intervention_name: "Biological: PD-1 antibody expressing mesoCAR-T cells")

Outcome.create(trial_id: 10, outcome_type: "primary", outcome_measure: "Incidence of treatment-related adverse events of infusion of autologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells", outcome_description: "Incidence of treatment-related adverse events are assessed using the NCI CTCAE V4.0 criteria.", outcome_timeframe: "2 years")
Outcome.create(trial_id: 10, outcome_type: "secondary", outcome_measure: "Objective response rate (ORR) of the treatment using PD-1 antibody expressing mesoCAR-T cells for advanced solid tumors", outcome_description: "Objective response rate (ORR) of the treatment is assessed according to the response evaluation criteria in solid tumor version 1.1 (RECIST1.1), which contains complete response (CR) and partial response (PR).", outcome_timeframe: "2 years")
Outcome.create(trial_id: 10, outcome_type: "secondary", outcome_measure: "Progression free survival", outcome_description: "Progression free survival is defined as the time from the day in which the patient is enrolled to the date on which tumor progresses or the date on which the patient dies for any cause.", outcome_timeframe: "2 years")
Outcome.create(trial_id: 10, outcome_type: "secondary", outcome_measure: "Overall survival", outcome_description: "Overall survival is defined as the time from the day in which the patient is enrolled to the date on which the patient dies for any cause.", outcome_timeframe: "2 years")

Condition.create(trial_id: 10, condition: "Advanced Solid Tumor")

Location.create(trial_id: 10, facility: "China", city: "Shanghai", state: "Shanghai", zip: "200072", country: "China")

#  END OF TRIAL DATA --------------------------------------------------

200.times do
    Patient.create(
        trial_id: Trial.all.sample.id,
        first_name: Faker::Name.first_name,
        last_name: Faker::Name.last_name,
        address: Faker::Address.full_address,
        gender: Faker::Gender.binary_type,
        weight: rand(100..200),
        height: rand(60..80),
        age: rand(18..65)
    )
end


puts "done seeding!"